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Abstract
Purpose of Review—Acute HIV infection (AHI), the earliest period after HIV acquisition, is
only a few weeks in duration. In this brief period, the concentration of HIV in blood and genital
secretions is extremely high, increasing the probability of HIV transmission. Although a
substantial role of AHI in the sexual transmission of HIV is biologically plausible, the significance
of AHI in the epidemiological spread of HIV remains uncertain.
Recent Findings—AHI is diagnosed by detecting viral RNA or antigen in the blood of persons
who are HIV seronegative. Depending on the setting, persons with AHI represent between 1% and
10% of persons with newly diagnosed HIV infection. The high concentration of virus during AHI
leads to increased infectiousness, possibly as much as 26 times greater than during chronic
infection. In mathematical models, the estimated proportion of transmission attributed to AHI has
varied considerably, depending on model structure, model parameters and the population. Key
determinants include the stage of the HIV epidemic and the sexual risk profile of the population.
Summary—Despite its brief duration, AHI plays a disproportionate role in the sexual
transmission of HIV infection. Detection of persons with AHI may provide an important
opportunity for transmission prevention.
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Introduction
Acute HIV infection (AHI) is the earliest phase of HIV infection, immediately following
acquisition of the virus and prior to seroconversion. The period of acute infection generally
lasts 3–4 weeks, during which both HIV RNA and p24 antigen (Ag) are present [1]. In the
absence of a developed immune response, AHI is further characterized by unfettered viral
replication, resulting in high concentrations of HIV recovered from blood and genital
secretions [1–8]. The concentration of HIV remains markedly elevated for up to 10–12
weeks post-infection, at which point it gradually declines to the levels observed in
established infection. The duration of the pre-seroconversion period and the magnitude of
the peak in viral load are variable. Seroconversion indicates a transition out of the acute
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phase and into the stage of early or recent infection in which antibodies are present and viral
load begins to decline [1, 4].
The high concentration of HIV in the genital tract during AHI leads to very efficient sexual
transmission [5, 7]. Consequently, AHI has a disproportionate role in HIV transmission,
despite the short duration of AHI. The significance of AHI in HIV transmission depends on
the stage of the epidemic and the characteristics of the underlying population. Despite this
potentially substantial role in sexual transmission, detection of AHI has not become routine,
primarily because of the challenges in diagnosis.
Diagnosis of Acute HIV Infection
The diagnosis of AHI is complicated by the absence of detectable HIV-specific antibodies.
In the window period, ranging from a few weeks to roughly 2 months in duration, a person
with AHI will test negative or indeterminate with traditional HIV antibody assays [4, 9–10].
Therefore, diagnosis of acute infection relies on the direct detection of the virus, typically
plasma HIV RNA detected with nucleic acid amplification tests (NAAT). Pooling samples
for RNA testing is a cost-containment strategy, significantly reducing per-patient costs for
this otherwise expensive assay [11]. Pooling also contributes to the feasibility of identifying
the relatively rare acute infection among the thousands of individuals who test negative for
HIV antibodies [3, 9, 12–14].
Many patients with AHI have symptoms of acute retroviral infection, but these symptoms
are often mild and non-specific. Targeted testing based on a combination of factors,
including reported risk behaviors, symptoms of acute retroviral infection, or STI syndromes,
such as genital ulcer disease, may facilitate identification of HIV-seronegative persons who
are most likely to benefit from testing for AHI [15–16]. The type of clinic and geographical
location may be important criteria for targeted testing in large programs [16]. The targeted
approach reduces resource utilization for population-level AHI screening.
Financial, technical, and logistical challenges impede widespread utilization of NAAT in
many high-prevalence, low-resource settings. The window period can be shortened by using
third-and fourth-generation indirect enzyme immunoassays (EIAs) that are sensitive to both
IgM and IgG, leading to detection of the host immune response earlier in the course of
infection [9]. Fourth-generation combination immunoassays are sensitive to p24 antigen and
IgM/IgG antibodies. Fourth-generation tests correctly identify 60–77% of acute infections,
generally missing persons with lower viral loads and very early infections [9, 17].
Combining standard rapid antibody tests with an “ultrasensitive” p24 antigen assay is
another alternative, detecting up to 90% of acute infections [12], but this procedure is
difficult to implement in practice. Point-of-care combination antibody/antigen tests are
under evaluation and could offer the benefit of same-day results.
AHI testing has been incorporated into routine testing procedures in several settings. Given
the short duration of AHI, persons with AHI generally represent a small proportion of
persons with negative HIV antibody tests. However, persons with AHI represent a
substantial proportion of all persons diagnosed with HIV infection, approximately 1–10%
[7, 9–11, 15–16, 18–20]. This proportion varies by setting. In the general counseling and
testing setting, the prevalence is often lower, as is the prevalence of established HIV
infection.[11, 16, 18] Enriching the population for higher risk persons, such as men who
have sex with men or persons attending STD clinics, increases the yield [10, 16, 18].
Targeted efforts in an STD clinic in Malawi and among febrile patients in Mozambique have
yielded substantial numbers of persons with AHI [15, 20–21].
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Biological Plausibility of AHI role in Transmission
Persons with AHI often exhibit markedly elevated viral loads, often exceeding 1 million
copies/milliliter [1–8]. Virus can be detected within the internal iliac lymph nodes within
two days of infection, with systemic viral dissemination occurring shortly thereafter [22].
The rapid consumption of target cells by HIV during AHI allows for significant viral
replication, leading to markedly elevated viral loads [6, 21]. In addition to host-specific
genetic factors that influence viremia during acute infection, viral factors may also play a
significant role [23]. The viremia expands exponentially for 2–3 weeks after infection,
unregulated in the absence of HIV-specific antibodies [2]. Among a cohort of Malawian
men with newly diagnosed HIV infection, the median blood viral burden among those with
AHI was >106 copies/ml, compared to 104.5 copies/ml observed among men with chronic
infection [21].
The heightened viral load in infected blood during AHI is mirrored in genital secretions [6–
8]. In men, the peak viral load is estimated to occur at 17 days in plasma and at 30 days in
semen [6]. Increased viral concentrations are also observed in female genital secretions
during the acute stage [8]. Cervical viral loads are strongly correlated with plasma viral
loads for the first 6 months of infection, and are significantly higher than levels in chronic
infection, approximately 0.7 – 1.1 log10 copies/ml above set point [8].
The elevated viral load in genital secretions in men and women provides the biological
mechanism for efficient sexual transmission of HIV during AHI [3, 6–7, 24–26]. Other
biological factors, including concomitant STI, also contribute to enhanced viral
transmissibility [7, 27]. As the majority of new HIV infections worldwide are acquired
through sexual transmission, the peak viremia and associated risk of onward transmission
make AHI a potential target for transmission prevention.
Empirical Evidence for the Role of AHI in Sexual Transmission
Despite the clear biological plausibility of a meaningful role of AHI in sexual transmission,
determining the proportion of transmission events attributable to AHI and estimating the
transmission rate by stage of infection have been difficult. The relative lack of empirical
data linking AHI to increased transmission reflects the dual challenges of identifying
individuals during or just after the brief acute stage and linking them to HIV-uninfected
sexual partners who subsequently seroconvert.
In the study of monogamous HIV serodiscordant couples in a population-based cohort in
Rakai, Uganda, the rates of transmission per coital act varied considerably by stage of
infection [28]. The rates per coital act were markedly higher during early infection (8.2/1000
within 2.5 months of seroconversion) decreasing to 1.5/1000 within 16 months of
seroconversion and 0.7/1000 during established infection. Rates increased again during late
stage infection (2.8/1000 within 6–24 months of death). The unadjusted rate of infection was
8.3 times higher in the first five months of infection than in established infection (95% CI:
3.4, 20.2). Adjustment for age and genital ulcer disease reduced the rate ratio slightly to 7.3
(95% CI 3.1, 17.3) [28].
The data from this cohort were reanalyzed with improved assumptions about sexual
behavior and transmission timing [29]. During AHI, the hazard rate of transmission was
estimated to be 26 times the rate during established HIV infection.
In a European cohort of discordant heterosexual couples, the probability of transmission per
coital act was significantly higher for penile-anal sex (126/1000 acts) in the first three
months following infection [30]. However, a change in the probability of transmission per
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coital act across stages was not observed for penile-vaginal sex, possibly because of limited
statistical power. A meta-analysis incorporating these and the Rakai data found per coital act
probabilities to differ by 2.5/1000 in early versus established infection [15].
Phylogenies reconstructed from sampled viral gene sequences can be used, cautiously, to
identify probable transmission clusters. In Quebec, reconstructed phyologenies were used to
identify likely transmission clusters among persons who seroconverted in the previous six
months [31]. Persons with treated or untreated established infection were also included.
Approximately half of the persons who seroconverted in the previous six months
cosegregated into 75 transmission clusters, while the remaining individuals had unique
sequences, suggesting that early HIV infection was responsible for approximately half of
HIV transmission events. Elsewhere, approximately 30–35% of persons with primary HIV
infection cosegregrated into phylogenetically related clusters [27, 32]. However, these data
may overestimate the proportion of transmission events attributable to AHI [33].
Mathematical Models
With limited empirical data, mathematical models have been a key tool for evaluating the
role of AHI in HIV epidemiology. Mathematical models have addressed two issues – the
relationship between viral load and male-to-female transmission probabilities and the impact
of AHI on predicted evolution of the HIV epidemic.
As one would expect, HIV RNA concentration in genital secretions has a profound effect on
predicted HIV transmission. In a probabilistic model, transmission was assessed as a
function of viral load based on HIV cell free viral concentrations in seminal plasma. The
probability of transmission was described with a log10 exponential function of viral load
with transmission probabilities of 0.3/1000 with 1000 copies of HIV RNA and 10/1000 with
100,000 copies [24]. The latter estimate is consistent with peak seminal viral burdens during
AHI [6–7].
Mathematical models to describe epidemic spread have used a variety of model structures in
varying populations and settings with differing parameter estimates (Table 1). Early
mathematical modeling studies supported a role of early HIV infection as a critical driving
force in the HIV epidemic [36]. In more recent studies, however, the impact of AHI in
mathematical models has varied considerably, due in part to the varying approaches used
[37, 39, 41, 43, 45].
The epidemic phase appears to be a critical determinant of the importance of AHI in sexual
transmission of AHI. In the early phase of an epidemic, acute/early HIV infection appears to
be responsible for a considerable share of transmission [34, 37, 43]. This observation is
logical, as a relatively larger proportion of infected persons have acute or early infection and
relatively few have progressed to late-stage disease [43]. In contrast, in models of endemic
HIV disease, the importance of AHI has been remarkably variable, with estimates ranging
from <1% to 82% [34, 36–37, 39, 41, 43, 45].
The characteristics of the population also greatly influence the potential role of acute/early
HIV infection. In contexts of high sexual partner concurrency or very high rates of partner
change, the role of AHI is substantially increased [29, 39]. Given its short duration, the
potential transmission due to AHI is limited to one person if the index case is in a
monogamous relationship for the duration of AHI. However, if the index case has
concurrent sexual partners, the risk of onward transmission is substantially increased. In
North Carolina, individuals with AHI named 2.5 times (95% CI: 2.1–3.0) as many current
sexual partners as individuals diagnosed with established HIV infection [46]. Importantly,
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concurrency operates not only as an individual factor for increased transmission, but also by
connecting multiple sexual dyads and clusters to one another at the population level [47].
Although mathematical models have been useful tools for assessing the role of AHI in HIV
sexual transmission, the quality of available data for use as model parameters is limited.
Mathematical models developed in the future would benefit greatly from more accurate data
about the relationship between disease state and transmissibility, as well as valid, reliable,
setting-specific data regarding sexual contact patterns.
Opportunities for Prevention Interventions
The challenges in the design of a prevention intervention targeted to persons with AHI are
numerous. First, as with any intervention dependent on testing, the success of the
intervention would hinge on persons’ decisions to seek HIV testing or aggressive
population-based programs (such as door-to-door testing). Second, the intervention would
undoubtedly require additional testing procedures, such as NAAT or antigen testing, to
detect AHI. Finally, the brief window period of AHI limits the proportion of persons who
would be identified with any testing program.
The potential benefits of an AHI testing program with a transmission prevention
intervention are substantial. In traditional testing, persons with AHI who present for HIV
testing will be informed that they are likely HIV-uninfected, and in most settings, will be
asked to return for repeat testing after several weeks or months. Such persons have little
incentive to alter behavior and may continue to contribute to onward HIV transmission.
Persons with unknown HIV status are believed to be responsible for a substantial proportion
of HIV transmission [48–49]. Indeed, test and treat has been suggested as a key approach for
HIV prevention [50]. Efforts to detect AHI are especially poignant in this context. AHI
reflects the earliest possible period of intervention after infection. Persons with AHI who are
informed of their status will know their HIV status from the earliest possible moment –
within a few days of HIV acquisition. The potential impact on transmission through
“positive prevention” may be substantial, even if the impact is primarily realized in the latter
phases of established HIV infection.
An intervention after AHI diagnosis is likely to require both behavioral and treatment
components. A behavioral intervention would need to be administered quickly and must
emphasize risk reduction, including partner notification, limiting new partner acquisition,
condom use, and possibly, abstinence during the acute phase. Treatment may also be
beneficial from a public health perspective. The treatment goal would be rapid reduction of
the viral load, especially in the genital tract, to limit the potential for onward transmission.
Other potential aspects of AHI treatment are discussed elsewhere in this volume [Fidler].
Conclusion
Persons with AHI contribute disproportionately to the onward sexual transmission of HIV
infection. While the magnitude of the proportion of HIV transmission attributable to persons
with AHI (or early HIV infection) is uncertain and variable, it is undoubtedly greater than
the prevalence of AHI. AHI represents a brief window of time and consequently, the
prevalence of AHI is low at any given time. However, the “hyperinfectious state” of persons
with AHI increases the likelihood of transmission to others.
The role of AHI in sexual HIV transmission varies with the epidemic stage and the
characteristics of the population. AHI appears to be especially important in populations with
newly introduced HIV infection. The significance of AHI also appears to increase in
Miller et al. Page 5













populations with high prevalence of concurrent partnerships and frequent partner change.
Even in a well-established HIV epidemic where the role of AHI generally appears to be less,
detection of persons with AHI provides an opportunity to intervene at the earliest possible
stage of infection.
Persons with AHI will continue to play an important role in the sexual transmission of HIV
for the foreseeable future. Improved awareness of AHI and implementation of routine
testing programs are needed. In addition, rapid, point-of-care diagnostics capable of
detecting a high proportion of persons before seroconversion would greatly facilitate
diagnosis. Currently, diagnosis of AHI is extremely challenging. But, ignoring AHI may
have substantial consequences for the future of the HIV epidemic.
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